Applied Molecular Transport Inc. (NASDAQ:AMTI) Brief Update on Interests
Applied Molecular Transport Inc. (NASDAQ:AMTI – Get Rating) was the target of a significant drop in short-term interest during the month of July. As of July 15, there was short interest totaling 1,710,000 shares, a decrease of 34.0% from the June 30 total of 2,590,000 shares. Based on an average daily trading volume of 421,800 shares, the days-to-cover ratio is currently 4.1 days. Currently, 6.9% of the company’s shares are sold short.
Wall Street analysts predict growth
Several research analysts have recently weighed in on AMTI shares. JMP Securities cut its price target on Applied Molecular Transport from $86.00 to $50.00 and set a “market outperform” rating for the company in a Thursday, May 19 research note. SVB Leerink cut its price target on Applied Molecular Transport from $60.00 to $21.00 and set an “outperform” rating for the company in a Friday, May 20 report. Finally, Jefferies Financial Group downgraded Applied Molecular Transport from a “buy” rating to a “hold” rating in a Thursday, July 7, report.
Applied Molecular Transport Price Performance
AMTI shares opened at $1.77 on Tuesday. Applied Molecular Transport has a one-year minimum of $1.74 and a one-year maximum of $33.28. The company has a market capitalization of $68.42 million, a P/E ratio of -0.56 and a beta of 1.24. The company has a fifty-day moving average of $2.89 and a 200-day moving average of $5.22.
Applied Molecular Transport (NASDAQ:AMTI – Get Rating) last released quarterly earnings data on Monday, May 9. The company reported ($1.10) EPS for the quarter, missing the ($0.70) consensus estimate of ($0.40). Analysts expect Applied Molecular Transport to post EPS of -2.96 for the current fiscal year.
Insider Buying and Selling at Applied Molecular Transport
Separately, director David Lamond acquired 33,000 shares in a trade on Friday, May 20. The shares were acquired at an average price of $3.08 per share, for a total transaction of $101,640.00. Following the completion of the purchase, the director now owns 1,044,019 shares of the company, valued at $3,215,578.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this hyperlink. In other Applied Molecular Transport news, Director David Lamond purchased 33,000 shares of the company in a trade dated Friday, May 20. The shares were purchased at an average price of $3.08 per share, for a total transaction of $101,640.00. Following the completion of the purchase, the director now directly owns 1,044,019 shares of the company, valued at $3,215,578.52. The acquisition was disclosed in a legal filing with the SEC, accessible via this hyperlink. Additionally, major shareholder Epiq Capital Group, Llc purchased 32,380 shares of the company in a transaction dated Thursday, May 12. The shares were acquired at an average price of $3.88 per share, with a total value of $125,634.40. Following the purchase, the insider now directly owns 8,307,755 shares of the company, valued at $32,234,089.40. Disclosure of this purchase can be found here. Over the past 90 days, insiders have bought 98,880 shares of the company worth $336,484 and sold 6,506 shares worth $19,323. 25.40% of the shares are held by insiders of the company.
Applied Molecular Transport Institutional Trading
Several hedge funds have recently bought and sold shares of AMTI. Amalgamated Bank bought a new stake in Applied Molecular Transport during the first quarter, valued at approximately $31,000. AdvisorNet Financial Inc. increased its stake in Applied Molecular Transport by 690.0% during the second quarter. AdvisorNet Financial Inc now owns 15,800 shares of the company valued at $46,000 after purchasing an additional 13,800 shares during the period. Quantbot Technologies LP increased its holdings in Applied Molecular Transport by 371.4% during the first quarter. Quantbot Technologies LP now owns 6,600 shares of the company valued at $49,000 after purchasing an additional 5,200 shares during the period. Acadian Asset Management LLC acquired a new stake in Applied Molecular Transport during the first quarter, valued at approximately $91,000. Finally, Ergoteles LLC increased its stake in Applied Molecular Transport by 53.0% during the first quarter. Ergoteles LLC now owns 17,404 shares of the company valued at $131,000 after purchasing an additional 6,031 shares during the period. Institutional investors hold 71.34% of the company’s shares.
Applied Molecular Transport Company Profile
(Get an evaluation)
Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. The Company’s lead product candidate is AMT-101, an oral selective gastrointestinal (GI) fusion of rhIL-10 that is in a Phase II clinical trial for the treatment of ulcerative colitis and associated inflammatory indications.
Get news and reviews for Applied Molecular Transport Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Applied Molecular Transport and related companies with MarketBeat.com’s free daily email newsletter.